Drugs / MVA-CMDR
MVA-CMDR
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT04301154 | Feb 2022 → Oct 2023 | HIV infectious disease | Henry M. Jackson Foundation for the Advancement of Military Medicine | Completed | No outcome recorded |
| Phase 1 | NCT02296541 | Dec 2014 → Nov 2016 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT01889719 | Jan 2014 → May 2015 | HIV infectious disease | Rockefeller University | Completed | No outcome recorded |
| Phase 1 | NCT01260727 | Feb 2010 → Dec 2013 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00376090 | Jul 2005 → Dec 2008 | HIV infectious disease | U.S. Army Medical Research and Development Command | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04066881 | Dec 2020 → Dec 2024 | HIV infectious disease | MRC/UVRI and LSHTM Uganda Research Unit | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01407497 Comparator | Aug 2011 → Mar 2013 | HIV infectious disease | Instituto Nacional de Saúde, Mozambique | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MVA-CMDR | “MVA-CMDR (Modified Vaccinia Ankara-Chiang Mai Double Recombinant) is a non-replicating, highly attenuated strain of Vaccina virus that has been genetically engineered to...” NCT04066881 ↗6“MVA-CMDR live attenuated modified vaccinia ankara vector (HIV-1 CM235 env/CM240 gag/pol); 1 x 10\^8 plaque-forming unit (pfu) administered IM by needle and syringe as a volume...” NCT01260727 ↗ |
| Known as | Modified Vaccinia Virus Ankara (MVA-CMDR) | “Modified Vaccinia Virus Ankara (MVA-CMDR)” NCT02296541 ↗ |
| Known as | MVA-CMDR Vaccine | “MVA-CMDR Vaccine” NCT01260727 ↗ |
| Modality | Vaccine | “a candidate HIV-1 vaccine based on a recombinant modified vaccinia Ankara viral vector expressing HIV-1 genes env/gag/pol.” PMID 21085591 ↗ Nov 2010 |
| Route | Intramuscular | “intra-muscularly (IM; 10(7) or 10(8) pfu)” PMID 21085591 ↗ Nov 2010 |